Bexarotene (LGD1069)

06/01/2006 - "In the prevention studies, in which the agents were administered beginning 5 days after MNU until the end of the study, targretin (150 mg/kg diet) and 4-methyl-UAB30 (200 mg/kg diet) were highly effective in decreasing cancer numbers by 75-85%. "
04/15/2005 - "In mouse mammary tumor virus-erbB2 mice treated with LGD1069, there was a marked decrease of COX-2 expression in both normal and malignant mammary tissues. "
05/01/2007 - "This suggests that bexarotene may have clinical utility in cancers where drug resistance by gene amplification is a major obstacle to successful therapy."
03/01/2008 - "Bexarotene has demonstrated chemopreventive and therapeutic efficacy towards mouse lung tumors. "
03/02/2006 - "Thus, bexarotene appears to be an effective preventive agent against lung tumor growth and progression."

06/01/2004 - "Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene."
05/01/2001 - "Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results."
10/01/2003 - "In order to evaluate the efficacy of bexarotene in cutaneous T-cell lymphomas, a pilot trial was initiated. "
02/01/2022 - "To establish real-world evidence about the safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma, we conducted a nationwide cohort study using data from post-marketing surveillance for bexarotene treatment. "
02/01/2022 - "Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: Real-world experience from post-marketing surveillance."

01/01/2022 - "Complete remission with bexarotene gel in unilesional folliculotropic mycosis fungoides located on the scalp."
05/01/2019 - "Early-stage mycosis fungoides (MF) has been effectively treated with bexarotene, an RXR-agonist, with overall response (OR) rates 54-67% and complete response (CR) rates 7-27%. "
03/01/2003 - "Topical bexarotene is a novel synthetic rexinoid with few side-effects that has shown efficacy for treatment of mycosis fungoides skin lesions in recent Phase II-III clinical trials. "
01/01/2008 - "Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides."
11/01/2019 - "Long-term control of mycosis fungoides of the hands with topical bexarotene: an update 15 years later."

05/01/2012 - "Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers."
03/15/2003 - "The efficacy of bexarotene in patients with refractory metastatic breast cancer is limited. "
01/01/2023 - "Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer."
01/01/2022 - "Bexarotene has also been evaluated in clinical trials for lung and metastatic breast cancer, wherein subsets of patients responded despite advanced disease. "
05/01/2005 - "The goal of this study was to evaluate the effect of bexarotene on development of acquired drug resistance and its role in overcoming acquired drug resistance in advanced breast cancer. "

10/01/2019 - "For the first time, these studies demonstrate a new, clinically relevant aerosolized bexarotene formulation that exhibits preventive efficacy against the major subtypes of lung cancer. "
03/02/2006 - "However, the chemopreventive efficacy of bexarotene has not been determined in mouse lung cancer models. "
03/02/2006 - "Bexarotene has shown efficacy in a phase I/II trial of non-small-cell lung cancers. "
11/01/2018 - "These results suggest that bexarotene inhibits the viability of lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway."
01/01/2017 - "Thereby, the overall results suggest that the bexarotene nanocrystals represent a potential source of medicine, which made bexarotene nanocrystals a promising candidate for the treatment of lung cancer."